we hope to bring a breakthrough therapy to the many patients with KRAS-driven cancers who are still underserved,” said Andrew Chi, M.D., Ph.D., Chief Medical Officer of Alterome. “We have ...

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today ...

SAN DIEGO, April 10, 2025--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies ...